Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases

J Biomed Sci. 2020 Jan 3;27(1):10. doi: 10.1186/s12929-019-0610-1.

Abstract

Siglec-15 is a member of the Siglec family of glycan-recognition proteins, primarily expressed on a subset of myeloid cells. Siglec-15 has been known to be involved in osteoclast differentiation, and is considered to be a potential therapeutic target for osteoporosis. Recent studies revealed unexpected roles of Siglec-15 in microbial infection and the cancer microenvironment, expanding the potential pathophysiological roles of Siglec-15. Chemical biology has advanced our understanding of the nature of Siglec-15 ligands, but the exact nature of Siglec-15 ligand depends on the biological context, leaving plenty of room for further exploration.

Keywords: Cancer; Macrophage; Microbial infection; Osteoclast; Sialic acid; Siglec-15.

Publication types

  • Review

MeSH terms

  • Communicable Diseases / genetics*
  • Communicable Diseases / pathology
  • Communicable Diseases / therapy
  • Gene Expression Regulation / genetics
  • Humans
  • Immunoglobulins / genetics*
  • Ligands
  • Membrane Proteins / genetics*
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Osteoclasts / metabolism
  • Osteoporosis / genetics*
  • Osteoporosis / pathology
  • Osteoporosis / therapy
  • Tumor Microenvironment / genetics

Substances

  • Immunoglobulins
  • Ligands
  • Membrane Proteins
  • SIGLEC15 protein, human